GSK Says No to GLP-1s, Prioritizes ‘Downstream Effects’ of Obesity

Why It Matters

The strategy redirects capital toward less competitive, high‑margin metabolic‑liver therapies, reshaping GSK’s role in the obesity market and influencing investor expectations.

Key Takeaways

• GSK skips GLP‑1 entry, cites crowded market.
• Focus shifts to obesity‑related liver disease treatments.
• Acquired efimosfermin alfa for $1.2 bn, $800 m milestones.
• 2025 revenue hit £32.7 bn, 7% growth.
• Targets >£40 bn revenue by 2031.

Pulse Analysis

The GLP‑1 class has become a headline‑grabbing arena for weight‑loss drugs, with companies such as Novo Nordisk and Eli Lilly racing to expand market share. GSK’s new chief executive, Luke Miels, signaled a deliberate retreat from this crowded space, arguing that late‑stage entry would strain resources and dilute the pipeline. While acknowledging the scientific appeal of GLP‑1 agonists, he emphasized that GSK’s strategic priorities lie elsewhere, opting to avoid direct competition and preserve capital for higher‑margin opportunities.

Instead of chasing weight reduction, GSK is betting on the downstream sequelae of obesity, particularly metabolic liver disease. In May 2025 the firm paid $1.2 billion for Boston Pharmaceuticals’ efimosfermin alfa, a Phase‑III‑ready FGF21 analog designed to treat steatotic conditions such as metabolic dysfunction‑associated steatohepatitis. The deal includes up to $800 million in milestone payments, underscoring GSK’s confidence in a niche yet growing therapeutic area. By targeting fatty‑liver pathology, the company aims to capture a segment where competition remains limited and reimbursement pathways are clearer.

Financially, GSK reported £32.7 billion in 2025 revenue, a 7 % constant‑currency increase driven by strong HIV and respiratory portfolios, while influenza sales fell sharply. The firm projects a modest 3‑5 % turnover rise and a 7‑9 % core profit lift for the current year, reaffirming its ambition to exceed £40 billion by 2031. Recent workforce reductions of up to 350 staff reflect a broader effort to reallocate talent toward high‑potential assets like efimosfermin. Investors will watch how this downstream focus translates into market share and long‑term earnings growth.